IMFINZI
Brand Name: IMFINZI™
Composition: Durvalumab500mg/10ml or 50mg/ml
Manufacturer: AstraZeneca
Product Description
Medical Info
IMFINZI™ contains Durvalumab, an advanced targeted immunotherapy medication classified as a programmed death-ligand 1 (PD-L1) blocking antibody. Developed by AstraZeneca, this prescription biologic acts by binding to PD-L1 proteins on cancer cells, preventing them from tricking the body’s immune system. This allows the patient’s own T-cells to recognize and attack the tumor effectively.IMFINZI™ is primarily indicated for treating specific types of advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancers. Administered exclusively via intravenous infusion under strict oncological supervision, it represents a critical milestone in modern cancer immunotherapy.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
